Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$882K | -$3.83M | -$9.45M | -$14.5M | -$15.3M | -$18.9M | -$14.9M | -$16.0M |
| Net income | -$7.39M | -$3.88M | -$9.46M | -$14.5M | -$15.3M | -$18.9M | -$14.9M | -$15.9M |
| EPS (diluted) | -$0.70 | -$0.28 | -$0.57 | -$16.50 | -$11.22 | -$12,509.11 | -$466.89 | -$35.75 |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$716K | -$3.55M | -$7.32M | -$13.5M | -$10.6M | -$14.1M | -$17.1M | -$13.8M |
| Capital expenditures | $0.00 | $20.1K | $17.9K | $5.75K | $4.42K | $3.90K | $4.19K | $18.2K |
| Free cash flow | -$716K | -$3.57M | -$7.34M | -$13.5M | -$10.6M | -$14.1M | -$17.1M | -$13.8M |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $283K | $7.24M | $14.0M | $5.00M | $10.1M | $549K | $6.46M | $7.20M |
| Total assets | $683K | $7.91M | $15.9M | $8.76M | $13.1M | $1.70M | $8.70M | $8.62M |
| Total liabilities | $1.23M | $311K | $1.91M | $2.59M | $4.92M | $6.13M | $2.52M | $4.10M |
| Shareholders' equity | -$549K | $7.60M | $13.9M | $6.16M | $8.13M | -$4.43M | $6.18M | $4.52M |
| Retained earnings | -$7.61M | -$11.5M | -$20.9M | -$35.4M | -$50.7M | -$69.6M | -$84.4M | -$100M |
| Shares (wtd avg diluted) | 12.7M | 16.5M | 23.9M | 878K | 1.36M | 1.51B | 31.8B | 443K |
Every figure is extracted from CNS Pharmaceuticals, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.